Sign in
Taking people in FranceNo phase

Registry collecting real-world data on lung cancer testing and treatment

Collects real-world data on molecular tumour testing in adults with advanced lung cancer.

Key facts

Who runs it
Hedera Dx SA
Where
Nancy, FranceSee the siteAlso in 3 other countries, 3 sites
Trial code
Registry title
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
Status
Recruiting
People taking part
1,000 people, planned
Started
1 Jun 2024
Expected to end
Dec 2031
Type of study
Observational
Record updated
31 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry is looking for adults with advanced lung cancer (non-small cell type) who have not yet had treatment for this advanced disease and plan to start first treatment.

Age
At least 18 years
Sex
All sexes can join
Disease stage
Non-small cell lung cancer that is locally advanced or has spread, cannot be removed by surgery, stage IIIB/C or IV
Earlier treatment
No earlier treatment for this advanced disease; first treatment is planned

Main reasons for not taking part

  • Another known cancer (other than the lung cancer, and early-stage non-invasive cervical cancer) in the 5 years before joining, except skin cancers
  • ECOG performance status above 2
  • Cannot sign the informed consent

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease
  • Intention-to-initiate first-line tumour therapy for this advanced disease
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • At least 18 years of age on the day of signing informed consent, and capable of signing informed consent

Who cannot take part

  • Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment

Where in France

Also in 3 other countries, 3 sites

  • Université de LorraineNancy, FranceContact: Dr. Christian Meisel, MD PhDTaking people

About the trial

What the trial wants to find out

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

The group in the trial

  • Advanced NSCLC patients

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Patient Registry Collecting the Clinical and Molecular Profiling Data of Patients With Locally Advanced and/or Metastatic, Unresectable, Stages IIIB/C or IV Non-small Cell Lung Cancer (NSCLC), Who Have Not Previously Been Treated for This Advanced Disease and Are Therefore Considered as Patients Receiving First-line Therapy.
Plain-language title
Registry collecting real-world data on lung cancer testing and treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
31 July 2025